Further investigation will be required to determine which CGD patient factors such as genotype, residual ROS production, concomitant treatment (e.g., IFNγ) and inflammatory complications are best suited for TNFα blockade and whether any of these mechanisms above can be exploited therapeutically in CGD and other chronic inflammatory conditions. This evidence concerns the gene TNF and chronic granulomatous disease.